A comparative study of 14‐day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first‐line Helicobacter pylori infection eradication: A randomized trial
出版年份 2020 全文链接
标题
A comparative study of 14‐day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first‐line
Helicobacter pylori
infection eradication: A randomized trial
作者
关键词
-
出版物
HELICOBACTER
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-10-12
DOI
10.1111/hel.12762
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori
- (2019) Jing Yang et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients
- (2019) Adrian G. McNicholl et al. Clinical Gastroenterology and Hepatology
- Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon?
- (2019) Amin Talebi Bezmin Abadi et al. Frontiers in Pharmacology
- Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori
- (2019) Takahisa Furuta et al. DIGESTION
- Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency
- (2018) David Y. Graham et al. Clinical Gastroenterology and Hepatology
- Prevalence of antibiotic resistance in Helicobacter pylori : a systematic review and meta-analysis in World Health Organization regions
- (2018) Alessia Savoldi et al. GASTROENTEROLOGY
- Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection
- (2018) Wen Zhong Liu et al. HELICOBACTER
- Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies
- (2018) David Y. Graham et al. Expert Review of Anti-Infective Therapy
- Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI
- (2018) David Y. Graham et al. HELICOBACTER
- Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis
- (2017) James K.Y. Hooi et al. GASTROENTEROLOGY
- Optimized high-dose amoxicillin–proton-pump inhibitor dual therapies fail to achieve high cure rates in China
- (2017) Dian-Chun Fang et al. Saudi Journal of Gastroenterology
- Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now?
- (2017) DavidY Graham et al. Saudi Journal of Gastroenterology
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori Infection
- (2015) Jyh-Chin Yang et al. Clinical Gastroenterology and Hepatology
- The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations
- (2015) Hirotoshi Echizen CLINICAL PHARMACOKINETICS
- Potent Gastric Acid Inhibition Over 24 Hours by 4-Times Daily Dosing of Esomeprazole 20 mg
- (2015) Shu Sahara et al. DIGESTION
- Molecular Approaches to Identify Helicobacter pylori Antimicrobial Resistance
- (2015) Francis Mégraud et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-lineHelicobacter pyloritherapy
- (2015) Wei Zhang et al. GUT
- Tailored versus Triple plus Bismuth or Concomitant Therapy as InitialHelicobacter pyloriTreatment: A Randomized Trial
- (2015) Liya Zhou et al. HELICOBACTER
- A Comparative Study of Sequential Therapy and Standard Triple Therapy for Helicobacter pylori Infection: A Randomized Multicenter Trial
- (2014) Liya Zhou et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients
- (2014) Zhiqiang Song et al. DIGESTIVE AND LIVER DISEASE
- Effect of dosing schemes of amoxicillin on eradication rates ofHelicobacter pyloriwith amoxicillin-based triple therapy
- (2013) Takahisa Furuta et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype
- (2012) M. Sugimoto et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The effects of varying acidity onHelicobacter pylorigrowth and the bactericidal efficacy of ampicillin
- (2012) E. A. Marcus et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report
- (2012) Peter Malfertheiner et al. GUT
- Role of Omeprazole Dosage and Cytochrome P450 2C19 Genotype in Patients Receiving Omeprazole-Amoxicillin Dual Therapy forHelicobacter pyloriEradication
- (2011) Jyh-Chin Yang et al. PHARMACOTHERAPY
- Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori Infection
- (2010) Takahisa Furuta et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Helicobacter pylori treatment in the era of increasing antibiotic resistance
- (2010) D. Y. Graham et al. GUT
- Mutations in penicillin-binding proteins 1, 2 and 3 are responsible for amoxicillin resistance in Helicobacter pylori
- (2008) E. Rimbara et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now